Enicepatide (CT-388)

Investigated uses

• Obesity, overweight and type 2 diabetes in clinical development.

Mechanism and hypotheses

• Enicepatide is a dual GIP and GLP-1 receptor agonist being developed for metabolic disease.

Human evidence

• A randomized, double-blind, placebo-controlled Phase 2 trial evaluated CT-388 in 469 adults with obesity or overweight. Limitations: The cited results were sponsor-reported topline findings; full peer-reviewed and regulatory review remain pending.

Safety highlights

• Gastrointestinal adverse events were reported in clinical development; the complete benefit-risk profile remains investigational.
• Long-term and uncommon risks are not established because no approved label or postmarketing record exists.

Regulatory context

Investigational; no FDA-approved enicepatide product.